Femasys claims FemVue Sono HSG has the potential to change the standard of care by moving the assessment to the office where all female infertility factors can be evaluated by her gynecologist.
Femasys president and CEO Kathy Lee-Sepsick said FemVue not only provides the physician an ability to expand services but allows for a comprehensive and appropriate plan of care, saving time and cost for the patient, both invaluable for couples dealing with infertility issues.
Advanced Gynecologic Surgery Institute president and medical director Charles Miller said FemVue allows, in the office, to precisely evaluate the cavity, myometrium, and for the first time fallopian tubes.
Along with the CE mark, the 510(k) clearance allows Femasys to expand commercialization efforts worldwide.
